<scp> <i>TP53</i> </scp> Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Authors
Antoine N. Saliba (ORCID: https://orcid.org/0000-0001-5134-7336)
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Antoine N. Saliba, Cecilia Arana Yi, Mehrdad Hefazi Torghabeh, J. Foran et al.
Journal
American Journal of Hematology
Topics
Myeloproliferative Neoplasms: Diagnosis and Treatment
article
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Antoine N. Saliba, Cecilia Arana Yi, Mehrdad Hefazi Torghabeh, J. Foran, Momna Warraich, Mrinal M. Patnaik, Kristen Beth McCullough, Talha Badar, Kebede H. Begna, Shaleen Kumar, Jeanne Palmer, Aref Al‐Kali, Naseema Gangat, Mahnoor Fatima, Abhishek Mangaonkar, Mithun V. Shah, William J. Hogan, Hassan Alkhateeb, Animesh Pardanani, Ayalew Tefferi
article en
Abstract
No abstract available for this paper.
Publication Tag
American Journal of HematologyVol. 101(4)
Institutions
Mayo Clinic (US), Jacksonville College (US), WinnMed (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US)
OpenAlex Percentile
Openalex Percentile: Top 50%
Topics
Myeloproliferative Neoplasms: Diagnosis and Treatment
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
<scp> <i>TP53</i> </scp> Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent — Antoine N. Saliba, Cecilia Arana Yi, et al. · American Journal of Hematology (2026) | TGRS Research Map | TGRS